NTLA vs CRSP
NTLA and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $1.75B | $4.97B |
| P/S | 25.8x | 1415.8x |
| Revenue growth (YoY) | 16.9% | -90.6% |
| Earnings growth (YoY) | 20.5% | -58.8% |
| EBIT margin | -651.7% | -18933.6% |
| ROE | -56.7% | -33.3% |
| ROIC | — | -32.6% |
| 1y total return | +1.6% | -15.9% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: NTLA vs CRSP
| 지표 | NTLA | CRSP |
|---|---|---|
| 최종 가치 | $9.9K | $36.5K |
| 총수익률 | -1.1% | +264.9% |
| CAGR | -0.1% | +13.8% |
| 변동성 | 78.4% | 63.9% |
| 샤프 | 0.34 | 0.45 |
| 소르티노 | 0.50 | 0.70 |
| 최대 낙폭 | -96.5% | -85.1% |
공통 거래일 2522일 기준, 2016-10-19 → 2026-10-30 · 무위험수익률 4.16% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)